Zosano Pharma (ZSAN) Says Data of ADAM Zolmitriptan for Acute Treatment of Migraine Published in Cephalalgia
Tweet Send to a Friend
Zosano Pharma Corp. (NASDAQ: ZSAN) announced today that Cephalalgia had published the Company’s positive results from our pivotal, multi-center, double ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
